Eurosurv. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020

[tetano]

• Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020
  
  
• Heli Harvala[SUP]1[/SUP] , Jennifer Mehew[SUP]2[/SUP] , Matthew L Robb[SUP]2[/SUP] , Samreen Ijaz[SUP]3[/SUP] , Steven Dicks[SUP]1,3[/SUP] , Monika Patel[SUP]4[/SUP] , Nicholas Watkins[SUP]5[/SUP] , Peter Simmonds[SUP]6[/SUP] , Tim Brooks[SUP]7[/SUP] , Rachel Johnson[SUP]2[/SUP] , Robin Gopal[SUP]4[/SUP] , David J Roberts[SUP]8,9[/SUP] , Maria Zambon[SUP]3[/SUP] , the NHS Blood and Transplant Convalescent Plasma Testing Group[SUP]10[/SUP]

Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

full article

https://www.eurosurveillance.org/con...#html_fulltext